Limited Benefit of Routine Clinical Follow‐Up for Relapse Detection in Diffuse Large B‐Cell Lymphoma Patients in Complete Remission Following First‐Line Treatment
American Journal of Hematology · 2025
DOI: 10.1002/ajh.27577 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Therese Lassen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Department of Hematology, Rigshospitalet, Denmark, Capital Region of Denmark, Department of Haematology, Christian Medical College, Vellore.
Abstract (Originalsprache)
Despite advances in treatment, approximately 15% of patients with diffuse large B‐cell lymphoma (DLBCL) who achieve complete remission (CR) after first‐line therapy will experience a relapse. However, there is no consensus on the optimal follow‐up strategies for detecting relapse after achieving CR. This population‐based study, based on the Danish Lymphoma Registry (LYFO), identified a total of 1634 patients diagnosed with DLBCL between 2010 and 2017, including 105 patients who achieved CR following first‐line R‐CHOP‐like therapy and subsequently relapsed. The median follow‐up time was 6 years (range 3–8 years). Most cases of relapse were symptomatic (83%), with B symptoms and peripheral lymphadenopathy being the most common. Asymptomatic relapses were identified through physical examination (1%), blood tests (3%), or imaging findings (13%). The proportion of relapses identified outside routine visits was 70%. Only 5% of scheduled routine visits led to a relapse diagnosis, whereas 74% of unscheduled visits initiated by the patient outside routine follow‐up resulted in relapse detection. Our findings highlight that systematic, scheduled monitoring of patients in remission after first‐line treatment contributes only modestly to the early detection of disease recurrence. Future studies should explore alternative methods of relapse surveillance rather than relying solely on pre‐scheduled clinical follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- Cancer Survivorship and Treatment Late Effects (CASTLE) - Danish Cancer Society National Research Center, Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Danish Medicines Agency, Copenhagen, Denmark.
- Deparment of Hematology, Zealand University Hospital, Roskilde, Denmark.
- Quality of Life Research Center, Department of Hematology, Odense University Hospital, Odense, Denmark and Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Lars M Pedersen
Förderung
- Department of Hematology, Rigshospitalet, Denmark
- Capital Region of Denmark
- Department of Haematology, Christian Medical College, Vellore
- Region Hovedstaden
Zitieren
APA
Lassen, T., Nielsen, T. H., von Heymann, A., Nielsen, L. K., Larsen, M. K., Gang, A. O., Johansen, C., & Pedersen, L. M. (2025). Limited Benefit of Routine Clinical Follow‐Up for Relapse Detection in Diffuse Large B‐Cell Lymphoma Patients in Complete Remission Following First‐Line Treatment. American Journal of Hematology. https://doi.org/10.1002/ajh.27577
Vancouver
Lassen T, Nielsen TH, von Heymann A, Nielsen LK, Larsen MK, Gang AO, et al. Limited Benefit of Routine Clinical Follow‐Up for Relapse Detection in Diffuse Large B‐Cell Lymphoma Patients in Complete Remission Following First‐Line Treatment. American Journal of Hematology. 2025. doi:10.1002/ajh.27577
BibTeX
@article{Lassen2025,
author = {Lassen, Therese and Nielsen, Torsten H and von Heymann, Annika and Nielsen, Lene K and Larsen, Morten K and Gang, Anne O and Johansen, Christoffer and Pedersen, Lars M},
title = {Limited Benefit of Routine Clinical Follow‐Up for Relapse Detection in Diffuse Large B‐Cell Lymphoma Patients in Complete Remission Following First‐Line Treatment},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.27577}
}
EUVIMED